ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

December 1, 2025

Study Completion Date

July 6, 2026

Conditions
Advanced EGFR Positive Solid Tumor
Interventions
BIOLOGICAL

ZZ06

"The phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg."

Trial Locations (5)

130000

NOT_YET_RECRUITING

Jilin Cancer Hospital, Changchun

130021

RECRUITING

The first Bethune hospital of Jilin University, Changchun

90048-1804

RECRUITING

Cedars Sinai Medical Center, Los Angeles

RECRUITING

Montefiore Medical Center, The Bronx

66205-2528

RECRUITING

Kansas University Cancer Center, Fairway

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Covance

INDUSTRY

lead

Changchun Intellicrown Pharmaceutical Co. LTD

INDUSTRY

NCT04412616 - ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies | Biotech Hunter | Biotech Hunter